American Gene Engineer Corp (AGEC) SEC Filing 10-Q Quarterly report for the period ending Tuesday, January 31, 2017

American Gene Engineer Corp

CIK: 1600784 Ticker: AGEC
Document and Entity Information - shares
3 Months Ended
Jan. 31, 2017
Mar. 22, 2017
Document and Entity Information  
Entity Central Index Key0001600784 
Entity Filer CategorySmaller Reporting Company 
Amendment Flagfalse 
Document Type10-Q 
Document Period End DateJan. 31, 2017 
Document Fiscal Year Focus2017 
Document Fiscal Period FocusQ1 
Current Fiscal Year End Date--10-31 
Entity Common Stock, Shares Outstanding 100,000,000

View differences made from one quarter to another to evaluate American Gene Engineer Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by American Gene Engineer Corp.


Assess how American Gene Engineer Corp's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

American Gene Engineer Corp's Definitive Proxy Statement (Form DEF 14A) filed after their 2017 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors